Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Fig. 1

Previous therapies and respective duration of disease control. For each patient, bar length and number represent the time to next treatment (in months). Section sign includes salvage chemotherapy followed by high-dose chemotherapy and ASCT; Asterisk indicates Bv induction followed by ASCT consolidation and Bv maintenance. Abbreviations: ICI immune checkpoint inhibitor, Bv brentuximab vedotin, ASCT autologous stem cell transplantation, AlloSCT allogeneic stem cell transplantation

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us